Valeant Recalls Cardizem CD Capsules for Dissolution Failures
Valeant Pharmaceuticals is recalling 206 bottles of Cardizem CD capsules because they failed to meet dissolution specifications, meaning the drug may not release properly.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class III, which indicates a low probability of adverse health consequences. The hazard is a manufacturing defect (dissolution failure) without reported injuries or illnesses, fitting the criteria for a moderate severity score.
Plain-English summary
Valeant Pharmaceuticals North America LLC is recalling 206 bottles of Cardizem CD (diltiazem hydrochloride) 180 mg capsules. The recall involves 30-count and 90-count bottles distributed nationwide in the USA and Puerto Rico. The specific lots affected are 18J018P and 18J029P, both with an expiration date of 08/2020.
The recall was initiated because the product failed to meet dissolution specifications. This means that high out-of-specification results were found when measuring the amount of drug released at certain time points. This defect could affect how the medication works in the body.
Consumers and healthcare providers should check their inventory for the specific lot numbers and NDC codes listed in the recall notice. If the product is found, it should be returned to the pharmacy or supplier for a refund or replacement. Patients should consult their healthcare provider for alternative treatment options if they are currently using this medication.
The recalled product
- Product
- CARDIZEM CD (DILTIAZEM HYDROCHLORIDE)
- Brand
- CARDIZEM CD
- Manufacturer
- Valeant Pharmaceuticals North America LLC
- Category
- Drug — Prescription Drug
- Affected units
- 206
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lots: a) 18J018P
- Exp 08/2020
- b) 18J029P
UPCs (1)
- 0301870796421
Distribution
Part of a larger recall action
This product is one of 5 recalled by Valeant Pharmaceuticals North America LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 5 products in this recall →Related recalls
Same brand · CARDIZEM CD
- ModerateValeant Recalls Cardizem CD Capsules for Dissolution Failures
FDA (Drugs) · 2019-02-20
- ModerateValeant Recalls Cardizem CD Capsules for Dissolution Failures
FDA (Drugs) · 2019-02-20
- ModerateValeant Recalls Cardizem CD Capsules for Dissolution Failures
FDA (Drugs) · 2019-02-20
Same manufacturer · Valeant Pharmaceuticals North America LLC
See all →- LowValeant Recalls Diltiazem HCl Capsules for Dissolution Failures
FDA (Drugs) · 2019-02-20
- ModerateValeant Recalls Cortaid 12-Hour Anti-itch Cream Due to cGMP Deviations
FDA (Drugs) · 2018-10-31
- ModerateValeant Recalls Cortaid Maximum Strength Cream Due to cGMP Deviations
FDA (Drugs) · 2018-10-31
- ModerateValeant Recalls Cortaid Intensive Therapy Cooling Spray Due to cGMP Deviations
FDA (Drugs) · 2018-10-31
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17